Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q1 Revenues Meet Reduced Expectations

NEW YORK, April 24 -  Microbead maker Luminex on Tuesday reported revenues of $3.9 million in the first quarter of 2001, up from $1.4 million in the year-ago quarter and in-line with its recently reduced forecast.

Last week the company slashed its revenue expectations for the first quarter of 2001, citing its partners’ delays in commercializing bioassay kits based on its technology. The company had initially forecasted that its first-quarter revenues would total $4.2 million to $4.9 million.

Overall, the company’s rate of growth slowed slightly compared to the fourth quarter of 2000, but it continued to market its LabMap technology for new commercial applications, signing 30 new customers in the first quarter of 2001, the Austin, Texas-based company said.

"Though we did not experience as steep an increase in quarter-to-quarter growth as we had previously, we continue to be encouraged by the rapid rate at which the markets we address are adopting our LabMap technology,” Mark Chandler, Luminex's CEO, said in a statement.

Luminex’s expenses increased in the quarter of 2000 to $6.3 million, from $3.4 million from the year ago period. These increases included $2.8 million in R&D expenses, compared with $1.3 million in the first quarter of last year, and $3.5 million in selling, general, and administrative expenses, compared with $2.1 million in the year-ago period. 

The company's first quarter losses widened to $4 million, or 14 cents per share, compared with $2.6 million, or 19 cents a share, in the first quarter of 2000.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.